Treprostinil reduces mitochondrial injury during rat renal ischemia-reperfusion injury
| Autor: | Evelyn Tolbert, Meiwen Ding, Nisanne S. Ghonem, Reginald Y. Gohh, Fatemeh Akhlaghi, Mark Birkenbach |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
SIRT3 Apoptosis Prostacyclin RM1-950 Mitochondrion Pharmacology Kidney urologic and male genital diseases Article Rats Sprague-Dawley medicine Animals cardiovascular diseases Antihypertensive Agents ATP synthase biology Renal ischemia urogenital system business.industry Acute kidney injury General Medicine medicine.disease Epoprostenol Rats Mitochondria Oxidative Stress Reperfusion Injury biology.protein Therapeutics. Pharmacology business Treprostinil medicine.drug |
| Zdroj: | Biomedicine & Pharmacotherapy, Vol 141, Iss, Pp 111912-(2021) Biomed Pharmacother |
| ISSN: | 0753-3322 |
| Popis: | Background: Renal ischemia-reperfusion injury (IRI) is a major factor contributing to acute kidney injury and it is associated with a high morbidity and mortality if untreated. Renal IRI depletes cellular and tissue adenosine triphosphate (ATP), which compromises mitochondrial function, further exacerbating renal tubular injury. Currently, no treatment for IRI is available. This study investigates the protective role of treprostinil in improving mitochondria biogenesis and recovery during rat renal IRI. Methods: Male Sprague Dawley rats were randomly assigned to groups: control, sham, IRI-placebo or IRI-treprostinil and subjected to 45 min of bilateral renal ischemia followed by 1–72 h reperfusion. Placebo or treprostinil (100 ng/kg/min) was administered subcutaneously via an osmotic minipump. Results: Treprostinil significantly reduced peak elevated serum creatinine (SCr) levels and accelerated normalization relative to IRI-placebo (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect